Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call

Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ET

LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its first quarter 2024 financial results after market close today, Tuesday, May 14, 2024. The Company will conduct a conference call today at 5:00 p.m. (Eastern Time) to review the results and provide an overview of the Company’s recent milestones and developments.

To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live call and the replay is 1180952. The replay will be available until May 28, 2024.

A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available on the Company’s website for 30 days following the call.

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Vivos Method represents the first clinically effective nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to severe OSA in adults. It has proven effective in over 42,600 patients treated worldwide by more than 1,950 trained dentists.

The Vivos Method includes treatment regimens that employ the proprietary CARE appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and/or palate. The three Vivos CARE devices open airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA in adults, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (VIP) program offers dentists training and other value-added services in connection with using The Vivos Method.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement additional revenue, sales and marketing strategies and other strategies aimed at increasing revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financing on reasonable terms when needed, if at all, or maintain its Nasdaq listing and (v) other risk factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.

Vivos Investor Relations and Media Contact: Julie Gannon Investor Relations Officer 720-442-8113 jgannon@vivoslife.com

Vivos®

Breathe New Life

+1 (888) 404-3177

Solutions

Adult Solutions

Children’s Health

How it Works

Am I a Candidate?

Company

About Vivos

News & Press

Research

Stockholders

Support

Find a Provider

For Providers

Contact Us

Legal

Privacy Policy

Corrective Statement

The Vivos CARE appliances (DNA, mRNA, mmRNA) are FDA 510(k) cleared (K230947) to treat mild-to-severe obstructive sleep apnea (OSA) in adults. The DNA appliance is FDA cleared (K234089) for moderate-to-severe pediatric OSA (Ages 6-17).

Copyright © 2026 Vivos Inc. All rights reserved.

t1.20

Pursuant to a March 2026 Settlement Agreement between Vivos and Ortho-Tain, the parties have agreed to post the following Corrective Statement for a period of not less than six (6) months:

Corrective Statement

In 2020, Vivos Therapeutics, Inc. filed a lawsuit in Colorado, Case No. 20 cv 1637. In July of 2020, Ortho-Tain, Inc. filed a lawsuit against Vivos in Illinois, Case No. 20 cv 0301.

Vivos and Ortho-Tain have agreed to settle and dismiss their respective lawsuits and, as part of the settlement, have agreed to issue this joint, Corrective Statement.

Vivos believes it made reasonable attempts to make proper disclaimers and disclosures in its continuing educational programs stating, in effect, that the patient cases shown had been treated with a variety of oral appliances from several different manufacturers, including naming the product companies. Ortho-Tain disagrees and claimed that Vivos failed to make proper attribution for certain cases being treated with Ortho-Tain products and further failed to give proper credit to Ortho-Tain’s founder, Dr. Earl Bergersen on a single specific handwritten drawing.

Between the latter part of 2019 and into 2021, Vivos’ continuing educational programs included the display of certain before-and-after-treatment photographs of select pediatric dental patients. Such continuing educational programs were entitled “Learn How the Vivos System Induces the Remodeling of Human Airway Tissues” and “2020 Wellness Summit” (the “Continuing Ed programs”). A Vivos “Patient Education Video” (PEV) that has been available from 2019 through the present that included images of pediatric dental patients along with a single handwritten drawing on pediatric craniofacial growth and development. Some of the names of children whose photographs were included in the Continuing Ed programs and PEV were: Isaac, Nicholas, Hunter, Paige, Michael, Allie, Emma, Ava, Mattthew, Ella and Ian. None of the aforementioned children had been treated with a Vivos appliance.

Vivos has agreed to stop using the photographs demonstrating those pediatric outcomes. Some, but not all, of the children depicted in the Continuing Ed programs and the PEV had used oral appliances supplied by Ortho- Tain, Inc.